A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)

A Phase IIa, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Examine MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Women

This study will assess the safety, tolerability, and efficacy of MK-6913 for the treatment of moderate-to-very-severe vasomotor symptoms (hot flashes or hot flushes) in postmenopausal women. The primary study hypothesis is that one or more doses of MK-6913 will result in a significantly greater reduction from baseline, compared to placebo, in the number of moderate to very severe hot flashes after 4 weeks of treatment.

Inclusion Criteria:

• Woman with at least 50 moderate to very severe hot flash episodes per week
• Postmenopausal
• Between 45 and 60 years of age if naturally menopausal, or between 35 and 60 if she underwent a bilateral oophorectomy
• Not receiving hormone therapy
• Has had both a normal mammogram and a normal Pap test in the past 6 months
• Generally healthy

Exclusion Criteria:

• A history of cancer, except for certain skin cancers
• Undiagnosed vaginal bleeding or any uterine endometrial disorder
• Currently uses tobacco products, or has used them in the last 6 months
• Has human immunodeficiency virus (HIV)